日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Association of post-operative ctDNA detection with outcomes of patients with early breast cancers

术后ctDNA检测与早期乳腺癌患者预后的相关性

Cutts, R; Ulrich, L; Beaney, M; Robert, M; Coakley, M; Bunce, C; Crestani, G W; Hrebien, S; Kalashnikova, E; Wu, H-T; Dashner, S; Sethi, H; Aleshin, A; Liu, M; Ring, A; Okines, A; Smith, I E; Barry, P; Turner, N C; Garcia-Murillas, I

Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer

IHC4评分与雌激素受体阳性乳腺癌新辅助化疗疗效的关系

Sheri, A; Smith, I E; Hills, M; Jones, R L; Johnston, S R; Dowsett, M

Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer

雌激素受体阳性乳腺癌中与芳香化酶抑制剂(AIs)耐药性发展相关的生物标志物变化

Arnedos, M; Drury, S; Afentakis, M; A'Hern, R; Hills, M; Salter, J; Smith, I E; Reis-Filho, J S; Dowsett, M

2008 NS–AUA ABSTRACTS

2008 NS–AUA 摘要

Smith, I E

Microarray-based comparative genomic hybridisation of breast cancer patients receiving neoadjuvant chemotherapy

对接受新辅助化疗的乳腺癌患者进行基于微阵列的比较基因组杂交分析

Pierga, J-Y; Reis-Filho, J S; Cleator, S J; Dexter, T; Mackay, A; Simpson, P; Fenwick, K; Iravani, M; Salter, J; Hills, M; Jones, C; Ashworth, A; Smith, I E; Powles, T; Dowsett, M

Mortality within 30 days of chemotherapy: a clinical governance benchmarking issue for oncology patients

化疗后30天内死亡率:肿瘤患者的临床治理基准问题

O'Brien, M E R; Borthwick, A; Rigg, A; Leary, A; Assersohn, L; Last, K; Tan, S; Milan, S; Tait, D; Smith, I E

Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer

乳腺癌一线化疗后细胞凋亡和增殖的早期变化

Archer, C D; Parton, M; Smith, I E; Ellis, P A; Salter, J; Ashley, S; Gui, G; Sacks, N; Ebbs, S R; Allum, W; Nasiri, N; Dowsett, M

Clinical and immunological assessment of Mycobacterium vaccae (SRL172) with chemotherapy in patients with malignant mesothelioma

恶性间皮瘤患者化疗联合牛分枝杆菌(SRL172)的临床和免疫学评估

Mendes, R; O'Brien, M E R; Mitra, A; Norton, A; Gregory, R K; Padhani, A R; Bromelow, K V; Winkley, A R; Ashley, S; Smith, I E; Souberbielle, B E

Vinorelbine--a clinical review

长春瑞滨——临床综述

Gregory, R K; Smith, I E

Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer.

持续低剂量沙利度胺:晚期黑色素瘤、肾细胞癌、卵巢癌和乳腺癌的 II 期研究

Eisen T, Boshoff C, Mak I, Sapunar F, Vaughan M M, Pyle L, Johnston S R, Ahern R, Smith I E, Gore M E